Posted by Michael Wonder on 24 Mar 2022
Abbott's FreeStyle Libre is first and only CGM system to gain expanded reimbursement in Japan to include all people with diabetes who use insulin
24 March 2022 - Without expanded coverage, continuous glucose monitoring reimbursements are limited to segment of people with diabetes who require insulin multiple times a day,
Abbott today announced that the Japanese Ministry of Health, Labour and Welfare has approved the expansion of reimbursement coverage for its FreeStyle Libre system to include all people with diabetes who use insulin at least once a day.
